THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Pharmacy Practice, Drug Safety & Regulatory Science • 3-TIER LEARNING GUIDE

Pharmacovigilance Programme of India (PvPI): ADR Classification, Naranjo Causality & LASA Safety

Editorial Body: THE INDIAN PHARMACIST Editorial Reference Reading Time: 9 min read Published: 2026-01-15 Last Updated: 2026-11-08 Status: Evidence-Sourced Educational Guide

1. Level 1 — Quick Learning Overview & Core Definition

Quick Concept Summary: Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of Adverse Drug Reactions (ADRs) or any other medicine-related problem. In India, the Pharmacovigilance Programme of India (PvPI) is coordinated by the Indian Pharmacopoeia Commission (IPC), Ghaziabad as the National Coordination Centre (NCC) operating through Adverse Drug Reaction Monitoring Centres (AMCs) nationwide.

2. Level 2 — Standard Study: Underlying Process & Major Classifications

Under the Rawlins-Thompson and extended Wills-Brown classification, ADRs are categorised into Type A (Augmented — dose-dependent, predictable from primary/secondary pharmacology, common, low mortality; e.g., insulin hypoglycaemia, beta-blocker bradycardia, warfarin bleeding) and Type B (Bizarre — non-dose-dependent within therapeutic range, unpredictable idiosyncratic/immunological hypersensitivity, rare, high mortality; e.g., penicillin anaphylaxis, carbamazepine SJS/TEN, chloramphenicol aplastic anaemia).

Major Pharmacological & Scientific Classifications

  • Type A (Augmented): Dose-related, predictable; managed by dose reduction.
  • Type B (Bizarre): Idiosyncratic or immunogenic (Gell & Coombs Types I–IV); managed by immediate and permanent drug withdrawal.
  • Type C (Chronic / Continuous): Cumulative dose- and time-dependent (e.g., Cushing's syndrome or osteoporosis from long-term corticosteroids; chloroquine retinopathy).
  • Type D (Delayed):Temporally delayed onset after exposure (e.g., teratogenesis from thalidomide/isotretinoin/valproate; secondary malignancy from alkylating agents).
  • Type E (End-of-Use / Withdrawal): Rebound hypertension after abrupt clonidine/beta-blocker cessation; adrenal crisis after abrupt steroid withdrawal.
  • Type F (Failure of Therapy): Often caused by CYP450 enzyme induction (e.g., Rifampicin causing oral contraceptive failure).

3. Original Scientific Illustration (PLATE-8.6: 8.6 Pharmacodynamics: Agonists, Antagonists, Dose-Response Curves & Therapeutic Index)

PHARMACODYNAMICS: AGONISTS, ANTAGONISTS, POTENCY (EC50) VS EFFICACY (Emax) & TI GRADED LOG DOSE–RESPONSE CURVES Log [Drug Concentration / Dose] → % Maximal Effect (E / Emax) Full Agonist (α = 1) + Competitive Antagonist (↑EC50, Same Emax) Partial Agonist (0 < α < 1) + Non-Competitive Antagonist (↓Emax) • Potency = Dose required for 50% effect (EC50 / ED50; horizontal axis) • Efficacy = Maximum ceiling effect achievable (Emax; vertical axis) Clinical Rule: Efficacy (Emax) is clinically more important than Potency. 4 MAJOR RECEPTOR SUPERFAMILIES & THERAPEUTIC INDEX 1. Ligand-Gated Ion Channels (Ionotropic — Milliseconds): GABA_A (Benzodiazepines), Nicotinic AChR, NMDA, 5-HT3 (Ondansetron) 2. G-Protein Coupled Receptors (GPCR / 7-TM — Seconds): Gs (↑cAMP: β1, β2), Gi (↓cAMP: α2, M2, Opioid), Gq (↑IP3/DAG/Ca2+: α1, M1/M3, AT1) 3. Enzyme-Linked / Receptor Tyrosine Kinases (Minutes–Hours): Insulin receptor (PI3K/Akt → GLUT4 translocation), EGFR, VEGFR 4. Intracellular / Nuclear Receptors (Hours–Days, Gene Transcription): Corticosteroids (Prednisolone), Thyroid (T3/T4), Vitamin D, PPAR-γ THERAPEUTIC INDEX (TI = TD50 / ED50) & NTI MONITORING • Wide TI (Safe): Penicillins, Paracetamol (at normal dose), PPIs • Narrow Therapeutic Index (NTI, TI < 2 — Requires TDM): Warfarin (INR), Digoxin, Lithium, Phenytoin, Vancomycin, Aminoglycosides
Figure 8.6: Pharmacodynamic receptor occupancy, intrinsic activity (alpha), Competitive vs Non-Competitive Antagonism, Potency (EC50) vs Efficacy (Emax), and Therapeutic Index (TI = TD50 / ED50).
Diagram Walkthrough: Drug-receptor interaction is governed by two independent parameters: Affinity (the strength of reversible drug-receptor binding, inversely proportional to the dissociation constant Kd) and Intrinsic Activity / Efficacy (alpha, the ability of the bound drug-receptor complex to activate downstream signal transduction). A Full Agonist (alpha = 1, e.g., Morphine at mu-opioid receptors, Adrenaline at beta-adrenoceptors) produces maximal response (Emax = 100%). A Partial Agonist (0 < alpha < 1, e.g., Buprenorphine, Aripiprazole, Pindolol) produces submaximal efficacy even at 100% receptor occupancy and acts as a competitive antagonist in the presence of a full agonist. A Competitive Antagonist (alpha = 0, e.g., Atropine, Naloxone, Losartan) binds reversibly to the orthosteric site, shifting the log dose-response curve to the right (increasing apparent EC50) without reducing Emax. A Non-Competitive or Irreversible Antagonist (e.g., Phenoxybenzamine, Aspirin on platelet COX-1, Omeprazole on H+/K+-ATPase) reduces functional receptor density, depressing Emax.

4. Level 3 — Advanced Clinical, Pharmacokinetic & Regulatory Reference

WHO-UMC & Naranjo Causality Assessment + ISMP High-Alert / LASA Governance: When evaluating a suspected ADR report (submitted via the IPC Suspected ADR Reporting Form or VigiFlow), causality is scored using the WHO-UMC criteria (Certain, Probable/Likely, Possible, Unlikely, Conditional/Unclassified, Unassessable) or the 10-question Naranjo Algorithm (>= 9 = Definite; 5–8 = Probable; 1–4 = Possible; <= 0 = Doubtful) based on temporal sequence, dechallenge (improvement upon stopping the drug), rechallenge, and exclusion of alternative causes. In hospital and community pharmacies, High-Alert Medications ('PINCH': Potassium chloride concentrate IV, Insulins, Narcotics/Opioids, Chemotherapeutics, Heparin/Anticoagulants) and Look-Alike Sound-Alike (LASA) pairs (e.g., Hydralazine vs Hydroxyzine; Dopamine vs Dobutamine; Vincristine vs Vinblastine) require physical segregation, Tall-Man Lettering (hydrALAZINE vs hydrOXYzine), and independent double-checks.

5. Common Misunderstandings & Clinical Pitfalls

Common Misunderstanding: Confusing an Adverse Drug Event (ADE) with an Adverse Drug Reaction (ADR). Per WHO definitions, an ADR occurs at normal doses used for prophylaxis, diagnosis, or therapy, whereas an ADE is broader and encompasses harm resulting from medication errors, overdoses, or improper administration.

6. Key Takeaways, Related Medicine Monographs & Calculators

Key Study & Practice Takeaways:
  • Never administer concentrated Potassium Chloride (KCl 15% / 2 mEq/mL ampoules) as an undiluted IV push; always dilute in large-volume IV fluid and infuse slowly (max 10 mEq/hr peripherally).
  • Use Tall-Man lettering and physical shelf separation for LASA medicines.
  • Report all serious ADRs (death, life-threatening, hospitalisation, disability, congenital anomaly) promptly to PvPI / IPC.

Related Medicine Monographs

💊 Phenytoin Sodium [11.13] →💊 Morphine & Fentanyl [7.20] → ⚖️ Compare Medicines →

Related Clinical Calculators

🧮 IV Drip Rate (drops/min) →🧮 Weight-Based IV Infusion (mcg/kg/min) →

7. Authoritative Medical & Regulatory References

  1. Indian Pharmacopoeia Commission (IPC) & CDSCO: Indian Pharmacopoeia (IP 2022) & National List of Essential Medicines (NLEM 2022), Ministry of Health and Family Welfare, Government of India (https://ipc.gov.in/ & https://cdsco.gov.in/).
  2. NCBI Bookshelf / National Library of Medicine: StatPearls Pharmacology, Physiology & Clinical Therapeutics Compendia (https://www.ncbi.nlm.nih.gov/books/).
  3. DailyMed (US National Library of Medicine): Official FDA Prescribing Information & Clinical Pharmacology Labelling (US Jurisdiction Reference) (https://dailymed.nlm.nih.gov/dailymed/).
  4. MedlinePlus, NHS Health Information, Cleveland Clinic Health Library & National Institute on Aging (NIA): Structured patient education and clinical communication references (MedlinePlus • NHS • Cleveland Clinic • NIA).